Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
$0.48
-36.9%
$0.38
$0.13
$1.00
$12.82M0.29182,400 shs1.58 million shs
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
$5.22
-5.1%
$5.54
$2.51
$6.97
$69.53M1.17118,105 shs104,721 shs
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
$0.56
+3.7%
$0.50
$0.26
$1.14
$19.63M1.5832,192 shs5,631 shs
Venus Concept Inc. stock logo
VERO
Venus Concept
$0.72
-5.3%
$0.82
$0.60
$4.70
$4.59M0.66452,973 shs10,084 shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
-15.65%+44.84%+130.99%+242.19%+16.94%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
+12.02%+15.55%-2.65%+31.26%+39.06%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
+1.89%+8.54%+8.43%+3.85%-48.43%
Venus Concept Inc. stock logo
VERO
Venus Concept
-0.96%-0.59%+16.99%-32.73%-71.48%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
0.173 of 5 stars
0.03.00.00.01.12.50.0
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
0.053 of 5 stars
0.02.00.00.00.01.70.6
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
0.7713 of 5 stars
2.03.00.00.01.91.70.6
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/AN/AN/AN/A
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/A
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/AN/A$3.80578.57% Upside
Venus Concept Inc. stock logo
VERO
Venus Concept
2.00
HoldN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/AN/AN/AN/A$0.15 per shareN/A
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/A$3.47 per shareN/A
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
$33.36M0.59N/AN/A$0.37 per share1.51
Venus Concept Inc. stock logo
VERO
Venus Concept
$76.35M0.06N/AN/A($2.43) per share-0.30

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
-$7.10M-$0.37N/AN/AN/A-172.38%-127.42%5/10/2024 (Estimated)
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
-$23.52M-$1.92N/AN/AN/AN/A-70.17%-64.68%5/6/2024 (Estimated)
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
-$10.83M-$0.31N/AN/AN/A-32.47%-52.50%-17.66%5/20/2024 (Estimated)
Venus Concept Inc. stock logo
VERO
Venus Concept
-$37.25M-$6.85N/AN/AN/A-48.79%N/A-36.21%5/15/2024 (Confirmed)

Latest GCTK, NVNO, VERO, and SSKN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2024N/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/AN/A  
3/28/2024Q4 2023
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/A-$0.10-$0.10-$0.10N/AN/A
3/27/2024Q4 2023
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/A-$0.04-$0.04$0.03N/A$8.69 million
2/29/2024Q4 2023
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/A-$0.32-$0.32-$0.32N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/AN/AN/AN/AN/A
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/AN/A
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/AN/AN/AN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
0.06
3.22
3.22
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/A
34.22
34.23
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
1.19
1.28
1.06
Venus Concept Inc. stock logo
VERO
Venus Concept
N/A
2.13
1.39

Ownership

Institutional Ownership

CompanyInstitutional Ownership
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
10.92%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
34.71%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
32.43%
Venus Concept Inc. stock logo
VERO
Venus Concept
87.41%

Insider Ownership

CompanyInsider Ownership
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
17.70%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
17.00%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
40.43%
Venus Concept Inc. stock logo
VERO
Venus Concept
51.39%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
626.76 million22.02 millionNot Optionable
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
1913.32 million11.05 millionOptionable
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
9935.06 million20.89 millionNot Optionable
Venus Concept Inc. stock logo
VERO
Venus Concept
3046.36 million3.09 millionNot Optionable

GCTK, NVNO, VERO, and SSKN Headlines

SourceHeadline
Venus Concept Announces Loan Purchase and Completion of First Phase of RefinancingVenus Concept Announces Loan Purchase and Completion of First Phase of Refinancing
finance.yahoo.com - April 24 at 7:48 PM
Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024
globenewswire.com - April 15 at 7:30 AM
Venus Concept Inc.: Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAXVenus Concept Inc.: Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
finanznachrichten.de - April 9 at 1:29 AM
Venus Concept Announces Approval For Venus Bliss MAX In Israel - Quick FactsVenus Concept Announces Approval For Venus Bliss MAX In Israel - Quick Facts
markets.businessinsider.com - April 8 at 10:21 AM
Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAXVenus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
globenewswire.com - April 8 at 7:30 AM
Ranking every single MoonSwatch thats ever droppedRanking every single MoonSwatch that's ever dropped
gq-magazine.co.uk - April 3 at 10:37 PM
On heels on Vero Beach, Sebastian growth, Fellsmere population to double in five years?On heels on Vero Beach, Sebastian growth, Fellsmere population to double in five years?
news.yahoo.com - April 3 at 10:37 PM
Venus Concept Announces Australian Regulatory Approval for Venus Versa ProVenus Concept Announces Australian Regulatory Approval for Venus Versa Pro
finance.yahoo.com - April 3 at 7:36 AM
Venus Concept Announces Australian Regulatory Approval for Venus Versa ProVenus Concept Announces Australian Regulatory Approval for Venus Versa Pro
globenewswire.com - April 3 at 7:30 AM
Venus Concept Inc.: Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsVenus Concept Inc.: Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
finanznachrichten.de - April 2 at 9:35 PM
VERO Stock Earnings: Venus Concept Misses EPS, Misses Revenue for Q4 2023VERO Stock Earnings: Venus Concept Misses EPS, Misses Revenue for Q4 2023
investorplace.com - April 1 at 1:03 PM
Venus Concept: Q4 Earnings SnapshotVenus Concept: Q4 Earnings Snapshot
houstonchronicle.com - April 1 at 9:42 AM
Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsVenus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
globenewswire.com - April 1 at 7:00 AM
Venus Concept Inc.: Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing RulesVenus Concept Inc.: Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
finanznachrichten.de - March 26 at 2:33 AM
Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing RulesVenus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
globenewswire.com - March 25 at 7:30 AM
Venus Concept Launches "NEXThetics" ProgramVenus Concept Launches "NEXThetics" Program
stockhouse.com - March 13 at 10:30 AM
Venus Concept Launches “NEXThetics” ProgramVenus Concept Launches “NEXThetics” Program
globenewswire.com - March 12 at 4:05 PM
Venus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesVenus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
globenewswire.com - February 27 at 4:05 PM
Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesVenus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
globenewswire.com - February 23 at 8:00 AM
Nasdaq Surges 300 Points; NVIDIA Posts Strong ResultsNasdaq Surges 300 Points; NVIDIA Posts Strong Results
msn.com - February 23 at 1:09 AM
Venus Concept Announces CE Mark for Venus Versa Pro in EuropeVenus Concept Announces CE Mark for Venus Versa Pro in Europe
finance.yahoo.com - February 22 at 10:08 AM
Venus Concept Announces CE Mark for Venus Versa Pro in EuropeVenus Concept Announces CE Mark for Venus Versa Pro in Europe
globenewswire.com - February 22 at 7:30 AM
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
finance.yahoo.com - February 20 at 10:42 AM
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
globenewswire.com - February 20 at 7:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

GlucoTrack logo

GlucoTrack

NASDAQ:GCTK
GlucoTrack, Inc., a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
enVVeno Medical logo

enVVeno Medical

NASDAQ:NVNO
enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.
STRATA Skin Sciences logo

STRATA Skin Sciences

NASDAQ:SSKN
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Venus Concept logo

Venus Concept

NASDAQ:VERO
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.